arbiter
JournalsAccount

ESG and Firm Performance: Non-linear Dynamics and Bidirectional Causality in Pharmaceutical Industry

M. Jayasree et al.

Global Business Review2026https://doi.org/10.1177/09721509251415307article
AJG 1ABDC B
Weight
0.50

Abstract

This study examines the bidirectional relationship between environmental, social and governance (ESG) performance and firm performance in the global pharmaceutical sector, employing a cross-lagged panel model for 255 firms from 2016 to 2022. Using Bloomberg ESG scores and three performance metrics, namely return on assets (RoA), return on invested capital (RoIC) and Tobin’s Q, we uncover nuanced, non-linear relationships. Results indicate that lagged ESG performance positively influences accounting-based measures (RoA and RoIC), supporting the notion that sustainability investments yield operational efficiencies over time. However, market-based valuation (Tobin’s Q) exhibits a U-shaped relationship, suggesting initial investor scepticism followed by long-term rewards for persistent ESG commitment. On the other hand, financial performance does not consistently drive subsequent ESG improvements, rejecting reverse causality. The inverted U-shaped relationship for RoIC aligns with the environmental Kuznets curve (EKC), revealing diminishing returns to ESG investments beyond a threshold. These findings contribute to stakeholder and signalling theories, demonstrating that ESG integration enhances financial resilience while highlighting market inefficiencies in pricing sustainability. The study advances the ESG–performance literature by providing sector-specific insights, emphasizing the strategic value of ESG in pharmaceuticals, where regulatory and reputational stakes are high. Policymakers and managers can leverage these insights to optimize ESG resource allocation and improve disclosure frameworks.

Open via your library →

Cite this paper

https://doi.org/https://doi.org/10.1177/09721509251415307

Or copy a formatted citation

@article{m.2026,
  title        = {{ESG and Firm Performance: Non-linear Dynamics and Bidirectional Causality in Pharmaceutical Industry}},
  author       = {M. Jayasree et al.},
  journal      = {Global Business Review},
  year         = {2026},
  doi          = {https://doi.org/https://doi.org/10.1177/09721509251415307},
}

Paste directly into BibTeX, Zotero, or your reference manager.

Flag this paper

ESG and Firm Performance: Non-linear Dynamics and Bidirectional Causality in Pharmaceutical Industry

Flags are reviewed by the Arbiter methodology team within 5 business days.

Evidence weight

0.50

Balanced mode · F 0.40 / M 0.15 / V 0.05 / R 0.40

F · citation impact0.50 × 0.4 = 0.20
M · momentum0.50 × 0.15 = 0.07
V · venue signal0.50 × 0.05 = 0.03
R · text relevance †0.50 × 0.4 = 0.20

† Text relevance is estimated at 0.50 on the detail page — for your query’s actual relevance score, open this paper from a search result.